Nasdaq

Early Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy

Castle’s innovative pipeline initiative to develop a genomic test aimed at guiding systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions ...
InfoQ

Effective Test Automation Approaches for Modern CI/CD Pipelines

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Vivek Yadav, an engineering manager from ...

Why Data Quality Should Start At The Beginning, Not The End

Data quality issues emerge from multiple failure points from development practices to production life cycle, each compounding ...
Forbes

Deconstructing Telemetry Pipelines: Streamlining Data Management For The Future

Telemetry pipelines may sound like a complex and relatively new concept, but they’ve been around for a long time. Telemetry pipelines play a crucial role in harnessing the power of telemetry data; ...
Business Wire

Early Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing the ability ...